Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | S100A4 | P26447 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24900737 | 0.87 | ALDH1A1 (0.56) | ALDH1A1HIF1ATSHRTDP1KMT2A | |
| SCHEMBL27671923 | 0.81 | ALDH1A1 (0.46) | ALDH1A1HIF1ATSHRTDP1KMT2A | |
| SCHEMBL13630905 | 0.80 | TDP1 (0.53) | ALDH1A1HIF1ATSHRTDP1KMT2A | |
| SCHEMBL3572666 | 0.80 | ALDH1A1 (0.60) | ALDH1A1TSHRTDP1KMT2ACYP3A4 | |
| SCHEMBL30168212 | 0.80 | ALDH1A1 (0.60) | ALDH1A1TSHRTDP1KMT2ACYP3A4 | |
| SCHEMBL30142204 | 0.79 | HSD17B10 (0.58) | ALDH1A1TSHRTDP1KMT2ACYP3A4 | |
| SCHEMBL30168161 | 0.79 | ALDH1A1 (0.46) | ALDH1A1HIF1ATSHRTDP1CYP3A4 | |
| SCHEMBL2815988 | 0.79 | ALDH1A1 (0.46) | ALDH1A1HIF1ATSHRTDP1CYP3A4 | |
| SCHEMBL29883144 | 0.78 | ALDH1A1 (0.41) | ALDH1A1HIF1ATSHRTDP1CYP3A4 | |
| SCHEMBL23580535 | 0.78 | ALDH1A1 (0.41) | ALDH1A1HIF1ATSHRTDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507510-B2 | Sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-8507510-B2 | Sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-20100076000-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-03-25 | — | — | US | disclosed |
| US-20100076000-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-03-25 | — | — | US | disclosed |
| EP-1673352-B1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES FOR USE AS CD AND/OR VEGF-INHIBITORS, THE PRODUCTION THEREOF AND THEIR USE AS DRUGS | BAYER SCHERING PHARMA AG (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-7338958-B2 | Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2008-03-04 | — | — | US | disclosed |
| US-7338958-B2 | Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2008-03-04 | — | — | US | disclosed |
| US-20070191393-A1 | Macrocyclic anilinopyrimidines with substituted sulphoximine as selective inhibitors of cell cycle kinases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007079982-A1 | (2 , 4 , 9-TRIAZA-1 (2 , 4 ) -PYRIMIDINA-3 ( 1 , 3 ) -BENZENACYCLONONAPHANE-3 4-YL) -SULFOXIMINE DERIVATIVES AS SELECTIVE AURORA KINASE INHIBITORS FOR THE TREATMENT OF CANCER | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-19 | — | — | WO | disclosed |
| EP-1673352-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES FOR USE AS CDK AND/OR VEGF INHIBITORS, THE PRODUCTION THEREOF AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-28 | — | — | EP | disclosed |
| US-20050176743-A1 | Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2005-08-11 | — | — | US | disclosed |
| WO-2005037800-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES FOR USE AS CDK AND/OR VEGF INHIBITORS, THE PRODUCTION THEREOF AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176743-A1 | Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | CDK2, CDK1, FLT1 | ALDH1A1 2681/4885HIF1A 404/4885TSHR 594/4885 |
| US-20100076000-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | CDK2, CDK1, FLT1 | ALDH1A1 2681/4885HIF1A 404/4885TSHR 594/4885 |
| US-20070191393-A1 | Macrocyclic anilinopyrimidines with substituted sulphoximine as selective inhibitors of cell cycle kinases | CCNI, CDK2, CDK1 | ALDH1A1 3242/4885HIF1A 2101/4885TSHR 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.